JP2009112314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009112314A5 JP2009112314A5 JP2009043222A JP2009043222A JP2009112314A5 JP 2009112314 A5 JP2009112314 A5 JP 2009112314A5 JP 2009043222 A JP2009043222 A JP 2009043222A JP 2009043222 A JP2009043222 A JP 2009043222A JP 2009112314 A5 JP2009112314 A5 JP 2009112314A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administration
- protein
- cyclin
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 101710091045 Envelope protein Proteins 0.000 claims 7
- 101710188315 Protein X Proteins 0.000 claims 7
- 102100021696 Syncytin-1 Human genes 0.000 claims 7
- 230000001177 retroviral effect Effects 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 108090000404 Cyclin G1 Proteins 0.000 claims 4
- 102000004012 Cyclin G1 Human genes 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 102000008186 Collagen Human genes 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 101800001271 Surface protein Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 108050006400 Cyclin Proteins 0.000 claims 2
- 102000016736 Cyclin Human genes 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100020873 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 101000884191 Homo sapiens Cyclin-G1 Proteins 0.000 claims 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 108010056243 alanylalanine Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001332 colony forming effect Effects 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 102000049816 human CCNG1 Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46457103P | 2003-04-21 | 2003-04-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513191A Division JP2006524057A (ja) | 2003-04-21 | 2004-04-21 | 疾患を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009112314A JP2009112314A (ja) | 2009-05-28 |
| JP2009112314A5 true JP2009112314A5 (enExample) | 2010-03-04 |
Family
ID=33310915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513191A Pending JP2006524057A (ja) | 2003-04-21 | 2004-04-21 | 疾患を処置するための方法および組成物 |
| JP2009043222A Pending JP2009112314A (ja) | 2003-04-21 | 2009-02-25 | 疾患を処置するための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513191A Pending JP2006524057A (ja) | 2003-04-21 | 2004-04-21 | 疾患を処置するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8052966B2 (enExample) |
| EP (2) | EP2353389B1 (enExample) |
| JP (2) | JP2006524057A (enExample) |
| AT (1) | ATE513471T1 (enExample) |
| CA (1) | CA2522359C (enExample) |
| ES (1) | ES2366617T3 (enExample) |
| WO (1) | WO2004093810A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002236517A1 (en) | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| US20070178066A1 (en) * | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20060253262A1 (en) * | 2005-04-27 | 2006-11-09 | Emiliem | Novel Methods and Devices for Evaluating Poisons |
| US7587843B2 (en) | 2006-06-06 | 2009-09-15 | Demers Alain P | Portable ice resurfacing device and method |
| DE102006035617A1 (de) * | 2006-07-31 | 2008-02-21 | Siemens Ag | Automatische Bestimmung von Tumorlast |
| JP2013541497A (ja) * | 2010-07-16 | 2013-11-14 | エペイウス バイオテクノロジーズ コーポレイション | 癌および他の障害のための標的指向ナノ粒子 |
| US9925276B2 (en) * | 2013-03-14 | 2018-03-27 | Epeius Biotechnologies Corporation | Thymidine kinase gene |
| CA2938431A1 (en) | 2014-02-05 | 2015-08-13 | Muffin Incorporated | Compartmented cryopreservation container and uses thereof |
| WO2015175375A1 (en) | 2014-05-13 | 2015-11-19 | Short Jay M | Conditionally active biological proteins |
| US20220184228A1 (en) * | 2019-04-12 | 2022-06-16 | Erlinda M. Gordon | Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2595915A (en) * | 1947-04-18 | 1952-05-06 | Texas Co | Internal-combustion engine |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1989009271A1 (en) | 1988-03-21 | 1989-10-05 | Viagene, Inc. | Recombinant retroviruses |
| US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| DE69129897T2 (de) | 1990-10-25 | 1998-12-17 | Clague Pitman Omaha Hodgson | Methode des gentransfers mittels retrotransposons |
| US5512421A (en) | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| AU663725B2 (en) | 1991-08-20 | 1995-10-19 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US6239351B1 (en) | 1993-07-01 | 2001-05-29 | Hoskins Manufacturing Company | Multi-wire self-diagnostic thermocouple |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| PT751988E (pt) | 1994-03-22 | 2000-05-31 | Immune Response Corp Inc | Producao e isolamento altamente eficientes de particulas virais |
| US5643770A (en) | 1994-07-21 | 1997-07-01 | Alexion Pharmaceuticals, Inc. | Retroviral vector particles expressing complement inhibitor activity |
| US6818439B1 (en) * | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| AU5320296A (en) | 1995-03-24 | 1996-10-16 | Genetic Therapy, Inc. | Modified viral envelope polypeptide |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US5800811A (en) | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| ATE285477T1 (de) | 1995-06-07 | 2005-01-15 | Inex Pharmaceutical Corp | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US5980935A (en) | 1996-05-15 | 1999-11-09 | Kirpotin; Dmitri | Cationic lipids and methods of use therefor |
| ES2216158T3 (es) | 1996-07-09 | 2004-10-16 | Canji, Inc. | Procedimiento para medir la infecciosidad viral. |
| US5962429A (en) | 1996-11-22 | 1999-10-05 | University Of Iowa | Complexes of adenovirus with cationic molecules |
| CA2595915A1 (en) | 1997-01-31 | 1998-08-06 | Schering Corporation | Methods for cultivating cells and propagating viruses |
| AU737727B2 (en) * | 1997-04-10 | 2001-08-30 | University Of Southern California | Modified viral surface proteins for binding to extracellular matrix components |
| US6004798A (en) | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
| DE69820465T2 (de) | 1997-06-23 | 2004-09-16 | Alza Corp., Mountain View | Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren |
| WO1999005303A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| FR2766706B1 (fr) | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| US20030027818A1 (en) | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| ES2287098T3 (es) * | 2000-03-02 | 2007-12-16 | University Of Southern California | Proteina ciclina g1 mutada. |
| US7060811B2 (en) * | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
| AU2002236517A1 (en) * | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| JP2005507684A (ja) | 2001-08-30 | 2005-03-24 | トレマック，リミティド ライアビリティー カンパニー | 望ましくない細胞の画像形成及び抹殺のための反陽子の生産及び送達 |
| US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
| US20090123428A1 (en) | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20070178066A1 (en) * | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| ES2426817T3 (es) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
| CN102801264B (zh) | 2012-09-04 | 2015-02-11 | 魏乐汉 | 永磁叠层电机 |
-
2004
- 2004-04-21 ES ES04760083T patent/ES2366617T3/es not_active Expired - Lifetime
- 2004-04-21 EP EP10011666.4A patent/EP2353389B1/en not_active Expired - Lifetime
- 2004-04-21 JP JP2006513191A patent/JP2006524057A/ja active Pending
- 2004-04-21 AT AT04760083T patent/ATE513471T1/de not_active IP Right Cessation
- 2004-04-21 EP EP04760083A patent/EP1619951B1/en not_active Expired - Lifetime
- 2004-04-21 US US10/829,926 patent/US8052966B2/en not_active Expired - Lifetime
- 2004-04-21 WO PCT/US2004/012302 patent/WO2004093810A2/en not_active Ceased
- 2004-04-21 CA CA2522359A patent/CA2522359C/en not_active Expired - Lifetime
-
2009
- 2009-02-25 JP JP2009043222A patent/JP2009112314A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009112314A5 (enExample) | ||
| Baker et al. | Designer oncolytic adenovirus: coming of age | |
| EP2633865B1 (en) | Use of interleukin-22 in treating viral hepatitis | |
| ES2358204T3 (es) | Adenovirus quiméricos para uso en el tratamiento del cáncer. | |
| JP7438552B2 (ja) | 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用 | |
| Collins et al. | Viral vectors in cancer immunotherapy: which vector for which strategy? | |
| JP2010528008A5 (enExample) | ||
| JP2017529326A5 (enExample) | ||
| JP7420751B2 (ja) | Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療 | |
| JP2012508698A5 (enExample) | ||
| Obajdin et al. | Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer | |
| CN105524139A (zh) | 高活性的肿瘤抑制剂及其制法和应用 | |
| CN113321736A (zh) | 一种长效化白介素15融合蛋白及其制备方法和应用 | |
| Zinovieva et al. | Oncolytic vesicular stomatitis virus: optimisation strategies for Anti-Cancer therapies | |
| CN104558119B (zh) | Yap蛋白抑制多肽及其应用 | |
| CN104311672B (zh) | 一种具有肿瘤细胞靶向性的抑制剂多肽 | |
| JP2014515595A5 (enExample) | ||
| JP2006524057A5 (enExample) | ||
| Mohr et al. | Gene therapy for malignant liver disease | |
| Wang et al. | Current status of gene therapy in melanoma treatment | |
| JP2007511534A5 (enExample) | ||
| JP2006519614A (ja) | 悪性かつ形質転換した哺乳動物細胞を選択的に殺すペプチド | |
| Gerspach et al. | Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands | |
| CN116059329A (zh) | 溶瘤病毒与car t细胞联合治疗血液肿瘤的方法 | |
| JP2007505601A5 (enExample) |